Antibiotic Therapy of an Infant With a Brevibacterium casei Ventriculoperitoneal Shunt Infection

Pediatr Infect Dis J. 2021 Dec 1;40(12):e519-e520. doi: 10.1097/INF.0000000000003267.

Abstract

We describe a newborn infant with hydrocephalus and a ventriculoperitoneal shunt infection caused by Brevibacterium casei. Essential for correct diagnosis was rapid species identification by matrix-assisted laser desorption/ionization time-of-flight, after initial report of coryneform bacteria. The patient responded well to vancomycin and rifampicin for 15 days. The shunt was not removed. Repeated cerebrospinal fluid cultures up to 4 months after therapy remained negative.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Brevibacterium / drug effects*
  • Brevibacterium / pathogenicity
  • Gram-Positive Bacterial Infections / cerebrospinal fluid
  • Gram-Positive Bacterial Infections / diagnosis*
  • Gram-Positive Bacterial Infections / drug therapy*
  • Humans
  • Hydrocephalus / microbiology
  • Infant, Newborn
  • Male
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Treatment Outcome
  • Ventriculoperitoneal Shunt / adverse effects

Substances

  • Anti-Bacterial Agents

Supplementary concepts

  • Brevibacterium casei